Elevance Health, Inc. $ELV Stock: Kestra Advisory Services LLC Raises Holdings

Kestra Advisory Services LLC increased its stake in Elevance Health, Inc. (NYSE:ELV) by 417.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 44,231 shares of the company’s stock after purchasing an additional 35,678 shares during the period. Kestra Advisory Services LLC’s holdings in Elevance Health were worth $17,198,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Activest Wealth Management increased its stake in shares of Elevance Health by 146.2% in the third quarter. Activest Wealth Management now owns 64 shares of the company’s stock valued at $25,000 after purchasing an additional 38 shares during the period. WealthCollab LLC lifted its holdings in shares of Elevance Health by 42.2% in the first quarter. WealthCollab LLC now owns 91 shares of the company’s stock valued at $27,000 after buying an additional 27 shares during the period. Kilter Group LLC bought a new position in shares of Elevance Health during the 2nd quarter valued at about $28,000. Main Street Group LTD acquired a new position in Elevance Health in the first quarter worth approximately $39,000. Finally, Elevation Wealth Partners LLC grew its holdings in shares of Elevance Health by 600.0% in the 2nd quarter. Elevation Wealth Partners LLC now owns 105 shares of the company’s stock worth $41,000 after acquiring an additional 90 shares during the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Insider Transactions at Elevance Health

In related news, EVP Ratnakar Lavu sold 1,300 shares of the stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $440.00, for a total transaction of $572,000.00. Following the completion of the transaction, the executive vice president directly owned 14,849 shares of the company’s stock, valued at approximately $6,533,560. This represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Mark Kaye sold 10,584 shares of the stock in a transaction that occurred on Thursday, October 22nd. The shares were sold at an average price of $440.13, for a total value of $4,658,335.92. Following the transaction, the chief financial officer directly owned 19,919 shares of the company’s stock, valued at $8,766,949.47. This trade represents a 34.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.34% of the stock is currently owned by insiders.

Key Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $29.02 from $27.06, and lifted forecasts for Q1 2027 and Q1 2028 to $11.73 and $12.61, respectively. An additional analyst also raised its Q2 EPS estimate, though the report did not provide the revised figure. Q2 EPS Estimate for Elevance Health Lifted by Analyst
• Neutral Sentiment: EVP Ratnakar Lavu sold 1,300 shares for $572,000, an 8.05% reduction in his holdings. He still directly owned 14,849 shares after the transaction, making the sale a limited insider-sentiment signal. SEC insider transaction filing
• Neutral Sentiment: A separate article considers what would need to be true for Elevance to be an attractive stock purchase, but the supplied article information does not state its conclusion. What Needs To Be True To Buy Elevance Health Stock?
• Negative Sentiment: Zacks Research lowered estimates for Q4 2026 EPS to $2.00 from $2.43, Q3 2027 to $6.01 from $6.70, and Q3 2028 to $7.09 from $7.75. These cuts temper the positive revisions and point to a less favorable outlook for some future quarters.

Elevance Health Stock Up 0.1%

Elevance Health stock opened at $426.17 on Monday. The company has a quick ratio of 1.47, a current ratio of 1.47 and a debt-to-equity ratio of 0.68. The stock has a market capitalization of $92.08 billion, a PE ratio of 18.17, a price-to-earnings-growth ratio of 2.03 and a beta of 0.63. Elevance Health, Inc. has a twelve month low of $274.84 and a twelve month high of $450.69. The company has a 50 day moving average of $412.92 and a 200-day moving average of $373.58.

Elevance Health (NYSE:ELV) last announced its earnings results on Wednesday, October 21st. The company reported $6.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.71 by $2.28. Elevance Health had a return on equity of 14.97% and a net margin of 2.55%. The business had revenue of $50.44 billion for the quarter, compared to analyst estimates of $49.28 billion. During the same quarter last year, the firm earned $6.03 EPS. Elevance Health’s revenue for the quarter was up .7% compared to the same quarter last year. On average, equities research analysts anticipate that Elevance Health, Inc. will post 29.15 EPS for the current fiscal year.

Elevance Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 18th. Stockholders of record on Friday, December 4th will be issued a $1.72 dividend. The ex-dividend date is Friday, December 4th. This represents a $6.88 annualized dividend and a dividend yield of 1.6%. Elevance Health’s dividend payout ratio (DPR) is presently 29.34%.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. TD Cowen upped their price target on Elevance Health from $465.00 to $495.00 and gave the company a “buy” rating in a research report on Friday, October 23rd. Wells Fargo & Company upped their price target on Elevance Health from $473.00 to $492.00 and gave the stock an “overweight” rating in a report on Tuesday, October 27th. The Goldman Sachs Group reiterated a “neutral” rating and set a $451.00 price target on shares of Elevance Health in a research note on Friday, October 23rd. Robert W. Baird increased their target price on shares of Elevance Health from $393.00 to $406.00 and gave the stock a “neutral” rating in a research report on Thursday, October 22nd. Finally, Barclays upped their target price on shares of Elevance Health from $469.00 to $472.00 and gave the stock an “overweight” rating in a research report on Thursday, October 22nd. Fifteen investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $456.48.

About Elevance Health

Elevance Health, Inc is a U.S. health benefits and services company. Formerly known as Anthem, Inc, it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans.

The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.

Elevance Health operates primarily in the United States, with health plans serving members across multiple states and access to broader provider networks through its Blue Cross Blue Shield affiliations.